Table 1.

T-cell proliferation assays, lymphocyte subsets, and vaccination responses before and after GT

Before GTAfter GTHealthy control ranges for 3-d stimulation
T-cell proliferation    
 Spontaneous (cpm) 103 115*  
 PHA (cpm) 2490 50 349* 18 906-417 388 
 aCD3 (cpm) 226 22 699* 187-122 682 
 aCD3/aCD28 (cpm) 2186 52 068* 1202-213 904 
Lymphocyte subsets    
 Total lymphocytes (×109/mL) (normal range: 1.0-2.8) 0.572 2.251 1.469/1.11§ 
 CD3 (×109/mL) (normal range: 0.7-2.1) 0.518 1.389 0.789/0.723§ 
 CD4 (×109/mL) (normal range: 0.3-1.4) 0.414 0.62 0.407/0.409§ 
 CD8 (×109/mL) (normal range: 0.2-0.9) 0.105 0.408 0.252/0.23§ 
 CD19 (×109/mL) (normal range: 0.1-0.5) 0.027 0.408 0.407/0.409§ 
Vaccination responses    
 Total pneumococcal titres (mg/L) (protective levels >20 mg/L) On immunoglobulin replacement therapy 4 43|| 
 Pneumococcus serotype-specific responses (protective levels >0.35 mg/L) On immunoglobulin replacement therapy ND Protective responses against 3/13 serotypes|| 
 Tetanus toxoid (IU/mL) (protective levels: 0.1-0.7) On immunoglobulin replacement therapy 0.14 2.51|| 
Before GTAfter GTHealthy control ranges for 3-d stimulation
T-cell proliferation    
 Spontaneous (cpm) 103 115*  
 PHA (cpm) 2490 50 349* 18 906-417 388 
 aCD3 (cpm) 226 22 699* 187-122 682 
 aCD3/aCD28 (cpm) 2186 52 068* 1202-213 904 
Lymphocyte subsets    
 Total lymphocytes (×109/mL) (normal range: 1.0-2.8) 0.572 2.251 1.469/1.11§ 
 CD3 (×109/mL) (normal range: 0.7-2.1) 0.518 1.389 0.789/0.723§ 
 CD4 (×109/mL) (normal range: 0.3-1.4) 0.414 0.62 0.407/0.409§ 
 CD8 (×109/mL) (normal range: 0.2-0.9) 0.105 0.408 0.252/0.23§ 
 CD19 (×109/mL) (normal range: 0.1-0.5) 0.027 0.408 0.407/0.409§ 
Vaccination responses    
 Total pneumococcal titres (mg/L) (protective levels >20 mg/L) On immunoglobulin replacement therapy 4 43|| 
 Pneumococcus serotype-specific responses (protective levels >0.35 mg/L) On immunoglobulin replacement therapy ND Protective responses against 3/13 serotypes|| 
 Tetanus toxoid (IU/mL) (protective levels: 0.1-0.7) On immunoglobulin replacement therapy 0.14 2.51|| 

PHA, phytohemagglutinin.

*

16 months after GT.

6 months after GT.

After GT, before vaccination.

§

11 months/16 months after GT.

||

After GT, after vaccination.

or Create an Account

Close Modal
Close Modal